Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea

FDA‑approved hypoglossal nerve stimulation is covered for adults (age ≥22) with moderate to severe OSA (AHI 15–65) who have BMI <35, predominantly obstructive events (central/mixed <25% of AHI), absence of complete concentric collapse on DISE, and documented CPAP failure or intolerance after consultation with a sleep expert. Coverage requires a qualifying PSG within 24 months, DISE without CCC, appropriate provider training/certification and facility accreditation; multiple specific cardiovascular, pulmonary, neurologic, pregnancy, device‑interaction and functional/mental‑status contraindications render the procedure non‑covered.

"Treatment with hypoglossal nerve stimulation is covered only when using an FDA‑approved hypoglossal nerve neurostimulation system."

Sign up to see full coverage criteria, indications, and limitations.